EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access

Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors

Manish R Sharma iD, John Powderly iD, Yasutoshi Kuboki iD, John H Strickler iD, Ruth Perets iD, Jonathan E Cohen iD, Judith Raimbourg, Takako Eguchi Nakajima iD, Noboru Yamamoto iD, Marcia Cruz-Correa, Bert O'Neil, François Ghiringhelli und 14 weitere

Journal of Clinical Oncology · 10.07.2026 · 44 (20) · 1876-1888

DOI: 10.1200/jco-25-01525 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.07.2026. Verfasst von Manish R Sharma und 25 weiteren Autor:innen. Beteiligte Einrichtung: START Center for Cancer Research-Midwest, Grand Rapids, MI. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Colorectal Neoplasms, Immunoconjugates, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The antibody-drug conjugate Temab-A comprises the c-Met–targeting antibody telisotuzumab conjugated to a novel topoisomerase 1 inhibitor payload, adizutecan. A first-in-human phase I study (ClinicalTrials.gov identifier: NCT05029882 ) of Temab-A in patients with advanced solid tumors whose disease has progressed is currently ongoing. We report results from all patients in the dose escalation and the monotherapy metastatic colorectal cancer (mCRC) dose expansion. METHODS Temab-A was administered intravenously once every 3 weeks as a monotherapy starting at 1.6 mg/kg in dose escalation. In mCRC dose expansion, patients with confirmed BRAF wild-type, microsatellite stable/mismatch repair-proficient mCRC were randomly assigned to 1.6 mg/kg, 2.4 mg/kg, or 3.0 mg/kg Temab-A once every 3 weeks. Primary end points included safety, pharmacokinetics, recommended phase II dose of Temab-A monotherapy, and Temab-A efficacy in patients with mCRC. RESULTS In total, 57 patients received ≥1 dose of Temab-A in dose escalation; 3.0 mg/kg once every 3 weeks was established as the maximum tolerated dose. Collectively, in dose escalation and dose expansion, 122 patients with mCRC received Temab-A (dose escalation, N = 29; randomized dose optimization expansion, N = 93). All patients experienced ≥1 treatment-emergent adverse event; the most frequent were gastrointestinal (78%) and hematologic (71%) toxicities. Treatment-related discontinuations and deaths were infrequent (10% and 3%, respectively). Across all doses in patients with mCRC, overall response rate was 15.6% (95% CI, 9.6 to 23.2), disease control rate was 74.6% (95% CI, 65.9 to 82.0), and duration of response was 5.9 months (95% CI, 4.1 to 10.5); responses were more frequent at doses of 2.4 mg/kg and 3.0 mg/kg once every 3 weeks. Median progression-free survival was 4.6 months (95% CI: 4.0, 5.4), and median overall survival was 10.4 months (95% CI, 8.9 to 13.1). CONCLUSION Temab-A at 2.4 mg/kg once every 3 weeks has a tolerable and manageable safety profile, with promising antitumor activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedColorectal NeoplasmsImmunoconjugatesNeoplasmsProto-Oncogene Proteins c-metAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDose-Response Relationship, DrugMaximum Tolerated Dose

Substanzen

Antibodies, Monoclonal, HumanizedImmunoconjugatesMET protein, humanProto-Oncogene Proteins c-met

Autor:innen und Institutionen

  • START Center for Cancer Research-Midwest, Grand Rapids, MI.
  • Carolina BioOncology Institute, Huntersville, NC.
  • Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.
  • Duke University Medical Center, Durham, NC.
  • Rambam Medical Center and Technion-Israel Institute of Technology, Haifa, Israel.
  • Hadassah Hebrew University Medical Center, Jerusalem, Israel.

ORCID-Profile: Manish R Sharma, John Powderly, Yasutoshi Kuboki, John H Strickler, Ruth Perets, Jonathan E Cohen, Takako Eguchi Nakajima, Noboru Yamamoto, Kanwal Raghav, Michael Cecchini, Jair Bar, Zoë Hunter, Michael Burns, Gladys Morrison-Thiele, Martha Neagu Aristide, Kevin J Freise, Carla Biesdorf, David Sommerhalder

Zitieren

APA

Sharma, M. R., Powderly, J., Kuboki, Y., Strickler, J. H., Perets, R., Cohen, J. E., Raimbourg, J., Nakajima, T. E., Yamamoto, N., Cruz-Correa, M., O'Neil, B., Ghiringhelli, F., Raghav, K., Cecchini, M., Bar, J., Hunter, Z., Burns, M., Blaney, M., Morrison-Thiele, G., …, & Sommerhalder, D. (2026). Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. Journal of Clinical Oncology, 44(20), 1876-1888. https://doi.org/10.1200/jco-25-01525

Vancouver

Sharma MR, Powderly J, Kuboki Y, Strickler JH, Perets R, Cohen JE, et al. Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. Journal of Clinical Oncology. 2026;44(20):1876-1888. doi:10.1200/jco-25-01525

BibTeX
@article{Sharma2026,
  author = {Sharma, Manish R and Powderly, John and Kuboki, Yasutoshi and Strickler, John H and Perets, Ruth and Cohen, Jonathan E and Raimbourg, Judith and Nakajima, Takako Eguchi and Yamamoto, Noboru and Cruz-Correa, Marcia and O'Neil, Bert and Ghiringhelli, François and Raghav, Kanwal and Cecchini, Michael and Bar, Jair and Hunter, Zoë and Burns, Michael and Blaney, Martha and Morrison-Thiele, Gladys and Aristide, Martha Neagu and Freise, Kevin J and Li, Rui and Li, Martha and Vasilopoulos, Athan and Biesdorf, Carla and Sommerhalder, David},
  title = {Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {20},
  pages = {1876--1888},
  doi = {10.1200/jco-25-01525}
}
Kostenlos starten →